AUTL
Autolus Therapeutics plc
There isn't enough reported data to score AUTL yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AUTL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
AUTL's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AUTL PE Valuation
AUTL has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AUTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect AUTL's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AUTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.97 | -$0.14 |
| Q2 2026 | -$1.06 | -$0.22 |
| Q1 2026 | -$1.09 | -$0.21 |
| Q4 2025 | -$1.08 | -$0.22 |
| Q3 2025 | -$0.83 | +$0.39 |
| Q2 2025 | -$0.84 | +$0.33 |
| Q1 2025 | -$0.88 | +$0.33 |
| Q4 2024 | -$0.86 | +$0.34 |
AUTL is still losing money, but far less than before: $0.97 per share over the past year, against $2.77 at its worst in late 2019.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AUTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.2M | +95% |
| Q2 2026 | $45.7M | +118% |
| Q1 2026 | $26.2M | +192% |
| Q4 2022 | $3.8M | +2025% |
| Q3 2022 | $2.4M | +904% |
| Q4 2021 | $180K | -55% |
| Q3 2021 | $236K | -65% |
| Q2 2021 | $1.6M | +461% |
AUTL's revenue has grown year over year for seven quarters in a row: $41M last quarter, up 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -106% | +232 points |
| Q2 2026 | -96% | +197 points |
| Q1 2026 | -227% | +499 points |
| Q4 2025 | -298% | N/A |
| Q3 2025 | -338% | N/A |
| Q2 2025 | -293% | N/A |
| Q1 2025 | -726% | N/A |
| Q1 2023 | -2738% | N/A |
AUTL's operating margin was โ106% last quarter, up 232 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AUTL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AUTL on profitability, with a higher operating margin.
AUTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.8M | +$52.5M |
| Q2 2026 | -$26M | +$54.1M |
| Q1 2026 | -$68M | +$15.8M |
| Q4 2025 | -$66.4M | -$17.4M |
| Q3 2025 | -$72.3M | +$14M |
| Q2 2025 | -$80.1M | -$28.1M |
| Q1 2025 | -$83.8M | -$42.8M |
| Q4 2024 | -$49M | -$22.7M |
AUTL has burned cash in almost every quarter: โ$180M over the past year, against โ$285M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AUTL on cash generation, producing positive trailing cash flow while its opponent burns cash.
AUTL Net Leverage
AUTL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AUTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 6.1 | Oversold |
AUTL's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AUTL PE vs Healthcare Sector
AUTL has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
HIMS has no meaningful PE right now: it lost money over the past year.
AUTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.57 | 24% below |
| 20 week MA | $1.76 | 32% below |
| 50 week MA | $1.63 | 27% below |
| 100 week MA | $1.73 | 31% below |
| 200 week MA | $2.71 | 56% below |
AUTL is in a downtrend: it's below all five of its weekly moving averages, and 56% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AUTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.6 | $8.90 | -35% |
| 2021 | $8.90 | $5.46 | -39% |
| 2022 | $5.46 | $1.86 | -66% |
| 2023 | $1.86 | $6.44 | +246% |
| 2024 | $6.44 | $2.26 | -65% |
| 2025 | $2.26 | $1.67 | -26% |
| 2026 YTD | $1.67 | $1.19 | -29% |
AUTL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to โ56% in 2021. It's down 42% so far in 2026.